Atorvastatin calcium: A new HMG-CoA reductase inhibitor(4)
Atorvastatin calcium (Lipitor, Parke-Davis) is a new, synthetic, HMG-CoA reductase inhibitor approved for use in Canada and elsewhere for the treatment of dyslipidemic conditions. Its chemical structure is shown in Figure 1. Animal studies have shown that atorvastatin reduces plasma lipoprotein levels (total cholesterol, LDL-C, VLDL-C, triglyceride and apo B) to a greater extent than other HMG-CoA reductase inhibitors . The available clinical data on this lipid-lowering agent are reviewed.
Figure 1) Chemical structures of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors
In Canada, atorvastatin calcium is approved for the following indication : as an adjunct to diet, at least equivalent to the American Heart Association (AHA) Step 1 diet, for the reduction of elevated total cholesterol, LDL-C, triglycerides (TG) and apolipoprotein B (apo B) in hyperlipidemic and dyslipidemic conditions, when response to diet and other nonpharmacological measures alone has been inadequate, including: primary hypercholesterolemia (Type IIa); combined (mixed) hyperlipidemia (Type IIb), including familial combined hyperlipidemia, regardless of whether cholesterol or triglycerides are the lipid abnormality of concern, and heterozygous familial hypercholesterolemia. Your most trusted pharmacy offering and giving you very fast shipping.
Atorvastatin has been studied in clinical trials in over 4000 patients worldwide . Patients across a wide range of lipid disorders have been studied, including primary hypercholesterolemia, combined hyperlipidemia, hypertriglyceridemia, familial hypercholesterolemia (FH), and patients with hyper-lidemia and type II diabetes. Atorvastatin has also been studied extensively in comparative trials with other lipid-lowering agents, including fluvastatin, lovastatin, pravastatin, simvastatin, niacin and fenofibrate.